Thursday, January 5, 2023 Daily Archives

Thermo Fisher to employ 5kL single-use bioreactor for Aslan’s eczema mAb

Aslan Pharmaceuticals has contracted Thermo Fisher to produce its atopic dermatitis candidate eblasakimab. Aslan’s lead candidate eblasakimab is being developed to treat atopic dermatitis (AD), the most common form of eczema. The monoclonal antibody (mAb) targets the IL-13 receptor α1 subunit (IL-13Rα1), which prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13), the key drivers of inflammation, central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin. The agreement will see…

Podcast: From platform to patient, CGTs must be more accessible

We sit down with Ori Biotech’s CEO Jason Foster to discuss the company’s paperless platform journey to commercialization and to delve deep into the challenges associated with accessing advanced therapies. This episode of the BioProcess Insider Expression Platform (BIEP) podcast brings you an in-depth conversation with Jason Foster, CEO of Ori Biotech. The company experienced a year of transition in 2022 with the closing of its $100 million Series B funding round and the expansion of its paperless cell and…

Swissmedic licenses expanded KBI mammalian cell manufacturing plant

KBI Biopharma says Swissmedic licensure for its expanded mammalian cell manufacturing facility in Geneva will be key to helping customers optimize processes and cut costs. The contract development and manufacturing organization (CDMO) was licensed in December after the Swiss drug regulator deemed KBI’s mammalian cell manufacturing plant was in compliance with current Good Manufacturing Practice (cGMP) standards. Chief operating officer Mike Landau said the licensure allows KBI to fully support clients in their next phases of growth and certifies the…

Moderna makes first-ever acquisition with $85m OriCiro buy

Moderna says the acquisition of Japan-based OriCiro will provide it with the tools needed for cell-synthesis and amplification of plasmid DNA. Moderna will buy OriCiro Genomics, a company founded in 2018 that focuses on cell-free DNA synthesis and amplification technologies, for $85 million, bolstering its messenger RNA (mRNA) technology offering. OriCiro is Moderna’s first acquisition since the company launched in 2010. The deal  comes two years after the success of its cell-free COVID-19 vaccine, mRNA-1273, which received emergency use authorization (EUA)…